79 related articles for article (PubMed ID: 8093030)
1. Combination of the chemotherapeutic agent 5-fluorouracil with an inhibitor of its catabolism results in increased micronucleus induction.
Stopper H; Kühnel A; Podschun B
Biochem Biophys Res Commun; 1994 Sep; 203(2):1124-30. PubMed ID: 8093030
[TBL] [Abstract][Full Text] [Related]
2. Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase.
Tuchman M; Ramnaraine ML; O'Dea RF
Cancer Res; 1985 Nov; 45(11 Pt 1):5553-6. PubMed ID: 4053028
[TBL] [Abstract][Full Text] [Related]
3. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice.
Desgranges C; Razaka G; De Clercq E; Herdewijn P; Balzarini J; Drouillet F; Bricaud H
Cancer Res; 1986 Mar; 46(3):1094-101. PubMed ID: 3943086
[TBL] [Abstract][Full Text] [Related]
4. Porcine recombinant dihydropyrimidine dehydrogenase: comparison of the spectroscopic and catalytic properties of the wild-type and C671A mutant enzymes.
Rosenbaum K; Jahnke K; Curti B; Hagen WR; Schnackerz KD; Vanoni MA
Biochemistry; 1998 Dec; 37(50):17598-609. PubMed ID: 9860876
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts.
Tatsumi K; Fukushima M; Shirasaka T; Fujii S
Jpn J Cancer Res; 1987 Jul; 78(7):748-55. PubMed ID: 3114201
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil.
Naguib FN; Hao SN; el Kouni MH
Cancer Res; 1994 Oct; 54(19):5166-70. PubMed ID: 7923135
[TBL] [Abstract][Full Text] [Related]
7. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.
Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G
Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071
[TBL] [Abstract][Full Text] [Related]
8. In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy.
Adams ER; Leffert JJ; Craig DJ; Spector T; Pizzorno G
Cancer Res; 1999 Jan; 59(1):122-7. PubMed ID: 9892196
[TBL] [Abstract][Full Text] [Related]
9. [Determination of dihydropyrimidine dehydrogenase in the prediction of toxic side effects of 5-fluorouracil].
Katona C; Rosta A; Tóth K; Fónyad G; Jeney A; Pandi E; Kralovánszky J
Orv Hetil; 1997 Jul; 138(29):1843-7. PubMed ID: 9280881
[TBL] [Abstract][Full Text] [Related]
10. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
11. [Intratumoral dihydropyrimidine dehydrogenase and its inhibition: a new approach in the pharmacokinetics of 5-fluorouracil].
Milano G; Etienne MC; Fischel JL
Ann Gastroenterol Hepatol (Paris); 1995; 31(2):103-5. PubMed ID: 7618831
[No Abstract] [Full Text] [Related]
12. Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer--in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Inoue K; Takao M; Watanabe F; Tarukawa T; Shimamoto A; Kaneda M; Sakai T; Fukushima M; Shimpo H; Yada I
Lung Cancer; 2005 Jul; 49(1):47-54. PubMed ID: 15949589
[TBL] [Abstract][Full Text] [Related]
13. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine.
Peck R; Wiggs R; Callaghan J; Wootton R; Crome P; Fraser I; Frick L; Posner J
Clin Pharmacol Ther; 1996 Jan; 59(1):22-31. PubMed ID: 8549030
[TBL] [Abstract][Full Text] [Related]
15. The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer.
Li Y; Mizutani Y; Shiraishi T; Nakamura T; Mikami K; Takaha N; Okihara K; Kawauchi A; Sakai T; Miki T
BJU Int; 2007 Mar; 99(3):663-8. PubMed ID: 17092280
[TBL] [Abstract][Full Text] [Related]
16. Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.
Komatsu T; Yamazaki H; Shimada N; Nagayama S; Kawaguchi Y; Nakajima M; Yokoi T
Clin Cancer Res; 2001 Mar; 7(3):675-81. PubMed ID: 11297264
[TBL] [Abstract][Full Text] [Related]
17. Enzymes of uracil catabolism in normal and neoplastic human tissues.
Naguib FN; el Kouni MH; Cha S
Cancer Res; 1985 Nov; 45(11 Pt 1):5405-12. PubMed ID: 3931905
[TBL] [Abstract][Full Text] [Related]
18. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy.
Jiang W; Lu Z; He Y; Diasio RB
Clin Cancer Res; 1997 Mar; 3(3):395-9. PubMed ID: 9815697
[TBL] [Abstract][Full Text] [Related]
19. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
Kim R; Tanabe K; Inoue H; Toge T
Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
[TBL] [Abstract][Full Text] [Related]
20. Induction of micronucleated erythrocytes in mouse peripheral blood after cutaneous application of 5-fluorouracil.
Zúñiga-González GM; Torres-Bugarín O; Zamora-Perez AL; Gómez-Meda BC; Ramos-Ibarra ML; Gallegos-Arreola P; Flores-García A; López-Uribe A
Arch Med Res; 2003; 34(2):141-4. PubMed ID: 12700011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
